Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
1 Spectacular Vanguard ETF to Buy With $420 During the S&P 500 Bull Market and Hold Forever
The S&P 500 (SNPINDEX: ^GSPC) is made up of 500 companies from 11 different sectors of the economy, but since it's weighted ...
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.7% Following Insider Selling
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...
Bluebird bio stock slides for second day on buyout news
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
VO: A Solid Mid-Cap Contender For Lofty Risk Adjusted Returns
Discover why Vanguard Mid-Cap ETF (VO) is a top buy with its diversification, low expense ratio, and strong momentum.